Research ReportA
Agilent Technologies (A): Replacement Cycle Momentum Builds
Agilent posted 6.3% core growth, 14% EPS growth, and raised FY26 guidance, but the stock still needs continued execution at 23.0x forward earnings.
Aug 26, 202620 MIN
TickerSpark Feed
diagnostics and research
Everything tagged "diagnostics and research" across the TickerSpark archives.
Research ReportNTRA
Natera (NTRA): Signatera Growth Supports a Hold
Natera posted 39% Q1 revenue growth and continued rapid oncology and women’s health expansion, but losses and a rich valuation keep the stock at Hold. The report sees strong long-term clinical momentum, yet limited margin of safety at the current price.
Aug 6, 202619 MIN
Research ReportIDXX
IDEXX Laboratories (IDXX): Recurring Diagnostics Drive the Buy Case
IDEXX delivered strong Q1 growth on the back of recurring diagnostics, premium instrument placements, and high customer retention. The stock still looks expensive, but the installed-base flywheel and raised 2026 guidance support a Buy.
Aug 4, 202620 MIN
Research ReportWAT
Waters Corporation (WAT): BD Deal Fuels Growth, Raises Risk
Waters is leaning into a larger life-science and diagnostics platform after its BD Biosciences and Diagnostic Solutions acquisition. Strong Q1 growth and raised guidance support a Buy, but leverage and a premium valuation keep the setup balanced.
Aug 4, 202619 MIN
Research ReportRVTY
Revvity (RVTY): AI-Led Recovery, But Valuation Is Full
Revvity is showing a credible medium-term recovery, powered by software, reproductive health, and high-content imaging. But the stock already prices in much of the improvement, leaving limited upside at current levels.
Aug 4, 202623 MIN
Research ReportTWST
Twist Bioscience (TWST): Growth Engine, But Valuation Is Rich
Twist Bioscience posted 19.3% revenue growth in fiscal Q2 2026 and raised full-year guidance, but it still faces losses and a demanding valuation. The stock earns a Hold as execution improves while investors wait for profitability.
Aug 3, 202622 MIN
Research ReportIQV
IQVIA Holdings (IQV): AI Data Scale Drives Growth
IQVIA is pairing healthcare data scale with accelerating Commercial Solutions growth and a record R&D backlog. The stock looks attractive for investors who can accept leverage in exchange for durable life sciences exposure.
Jul 28, 202619 MIN
Research ReportTMO
Thermo Fisher Scientific (TMO): Buy on Pullbacks
Thermo Fisher remains a scaled, resilient life sciences compounder with strong cash generation and raised 2026 guidance. The stock looks attractive on quality, but valuation and leverage argue for patience rather than chasing it higher.
Jul 23, 202619 MIN
Research ReportDHR
Danaher (DHR): Improving Growth, Rich Valuation
Danaher is seeing better operating momentum across Life Sciences, Diagnostics, and Biotechnology, but the stock still trades at a premium that limits upside. The report keeps a Buy rating with fair value set at $225.
Jul 22, 202621 MIN
Research ReportMEDP
Medpace Holdings (MEDP): Growth Quality vs. Booking Risk
Medpace is still delivering strong revenue, margin, and cash flow growth, but softer bookings and a rich valuation keep the stock in Hold territory. The business quality is high, yet the current setup looks better on pullbacks than at full price.
Jul 22, 202621 MIN
On-Demand Research
Need research on a stock not covered here?
Generate AI research on any ticker — grades, price targets, and full analysis in minutes.
Open the GeneratorFor Active Investors
Stock research for every investor
- Reports on any stock
- Daily market intelligence
- AI analyst in your pocket
- Portfolio analysis tools
Cancel anytime
Today's Top MoverLITE
▲11.04%
Lumentum Holdings Inc. · $978.53